HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Holding AG

http://www.roche.com

Latest From Roche Holding AG

Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds. 

Financing Immune Disorders

Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

China Research & Development

Asia Deal Watch: Ono Calls On PRISM BioLab’s Capabilities

Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.

Deal Watch Business Strategies

Stock Watch: Core Business Drags As Roche Disappoints And Sanofi Reclassifies

After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on those large components of pharma, Sanofi’s reclassification may bring some unwelcome attention.

Stock Watch Sales & Earnings
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Other Names / Subsidiaries
    • Adheron Therapeutics
    • Anadys Pharmaceuticals, Inc.
    • Ariosa Diagnostics
    • Arius Research, Inc.
    • Boehringer Mannheim
    • CAPP Medical
    • Chugai Pharmaceutical Co., Ltd.
    • Dutalys GmbH
    • Flatiron Health
    • Foundation Medicine
    • GenMark Diagnostics, Inc.
    • Genentech Inc.
    • GeneWEAVE BioSciences, Inc.
    • Genia Technologies, Inc.
    • GlycArt Biotechnology
    • Hoffmann-La Roche
    • Inflazome Ltd.
    • Ignyta, Inc. (RXDX) (Actagene Oncology, Inc
    • NexDx, Inc.)
    • Inception 5
    • InterMune, Inc.
    • Inflazome Ltd.
    • IQuum, Inc.
    • Jecure Therapeutics
    • Kapa Biosystems, Inc.
    • Marcadia Biotech, Inc.
    • Medingo Ltd.
    • Memory Pharmaceuticals Corporation
    • mtm laboratories AG
    • Piramed Pharma
    • Santaris Pharma A/S
    • Seragon Pharmaceuticals
    • Signature Diagnostics AG
    • Stratos Genomics
    • Syntex Corporation
    • Tanox, Inc.
    • Tensha Therapeutics, Trophos SA
    • Ventana Medical Systems, Inc.
    • Viewics, Inc.
UsernamePublicRestriction

Register